MCID: UNC014
MIFTS: 27

Unicentric Castleman Disease malady

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Unicentric Castleman Disease

Aliases & Descriptions for Unicentric Castleman Disease:

Name: Unicentric Castleman Disease 50
Localized Castleman Disease 50 56
Unicentric Angiofollicular Ganglionic Hyperplasia 50
Localized Angiofollicular Lymphoid Hyperplasia 69
Unicentric Angiofollicular Lymph Hyperplasia 50
Angiolymphoid Hyperplasia 69

Classifications:



External Ids:

Orphanet 56 ORPHA93685
ICD10 via Orphanet 34 D36.0

Summaries for Unicentric Castleman Disease

NIH Rare Diseases : 50 unicentric castleman disease (ucd) is a rare condition that affects the lymph nodes and related tissues. it is a form of castleman disease that is "localized" to a single set of lymph nodes (as opposed to multicentric castleman disease which has more widespread effects). ucd often starts as an enlarged lymph node. depending on the location of this enlarged node, some people will have no additional features of the condition, while others will develop symptoms when it pushes on nearby organs and/or tissues. the exact underlying cause of ucd is currently unknown. treatment typically includes surgical removal of the affected lymph node. last updated: 6/24/2015

MalaCards based summary : Unicentric Castleman Disease, also known as localized castleman disease, is related to castleman disease and multicentric castleman disease. An important gene associated with Unicentric Castleman Disease is CRP (C-Reactive Protein), and among its related pathways/superpathways is Folate Metabolism. The drugs Ganciclovir and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include lymph node and prostate.

Related Diseases for Unicentric Castleman Disease

Diseases related to Unicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)
id Related Disease Score Top Affiliating Genes
1 castleman disease 11.5
2 multicentric castleman disease 11.1
3 microcytic anemia 10.0
4 prostate cancer 9.9
5 nephrotic syndrome 9.9
6 prostatitis 9.9
7 cervicitis 9.9
8 thymoma 9.9
9 pancreatitis 9.9
10 anaplastic ganglioglioma 9.8 CRP SAA4
11 urethral obstruction sequence 9.8 CRP SAA4
12 cutaneous sclerosis 9.7 CRP SAA4

Graphical network of the top 20 diseases related to Unicentric Castleman Disease:



Diseases related to Unicentric Castleman Disease

Symptoms & Phenotypes for Unicentric Castleman Disease

Drugs & Therapeutics for Unicentric Castleman Disease

Drugs for Unicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
2
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
4 Ganciclovir triphosphate Phase 4,Phase 2
5 Antiviral Agents Phase 4,Phase 2,Early Phase 1
6
Suramin Approved Phase 2 145-63-1 5361
7 Siltuximab Approved Phase 1, Phase 2, Early Phase 1 541502-14-1
8
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
9
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
10
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
11
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
12
Zidovudine Approved Phase 2 30516-87-1 35370
13
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
14
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
Everolimus Approved Phase 2 159351-69-6 6442177
17
Lenograstim Approved Phase 2 135968-09-1
18
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
19
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
20 Pomalidomide Approved Phase 1, Phase 2 19171-19-8
21
Doxil Approved June 1999 Phase 2,Phase 1 31703
22 Anthelmintics Phase 2
23 Pharmaceutical Solutions Phase 2,Phase 1
24 Immunoglobulins Phase 1, Phase 2, Early Phase 1
25 Antibodies, Monoclonal Phase 1, Phase 2, Early Phase 1
26 Antibodies Phase 1, Phase 2, Early Phase 1
27 Antiparasitic Agents Phase 2
28 Antiprotozoal Agents Phase 2
29 interferons Phase 2
30 Alkylating Agents Phase 2,Phase 1
31 glucocorticoids Phase 2,Phase 1
32 Adjuvants, Immunologic Phase 2
33 Topoisomerase Inhibitors Phase 2,Phase 1
34 Nucleic Acid Synthesis Inhibitors Phase 2
35 Hormone Antagonists Phase 2,Phase 1
36 Hormones Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 2,Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 2,Phase 1
40 Anti-Bacterial Agents Phase 2,Phase 1
41 Etoposide phosphate Phase 2,Phase 1
42 Anti-HIV Agents Phase 2,Early Phase 1
43 Immunosuppressive Agents Phase 2,Phase 1
44 Anti-Inflammatory Agents Phase 2,Phase 1
45 Interferon-alpha Phase 2
46 Antifungal Agents Phase 2
47 Antimetabolites Phase 2
48 Anti-Retroviral Agents Phase 2,Early Phase 1
49 Antibiotics, Antitubercular Phase 2,Phase 1
50 Reverse Transcriptase Inhibitors Phase 2

Interventional clinical trials:

(show all 26)
id Name Status NCT ID Phase
1 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4
2 Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease Completed NCT00002652 Phase 2
3 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2
4 Tocilizumab for KSHV-Associated Multicentric Castleman Disease Recruiting NCT01441063 Phase 2
5 TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03043105 Phase 2
6 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting NCT00092222 Phase 2
7 Siltuximab in Schizophrenia Recruiting NCT02796859 Phase 1, Phase 2
8 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Active, not recruiting NCT01400503 Phase 2
9 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Active, not recruiting NCT01024036 Phase 2
10 Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy Terminated NCT00127569 Phase 2
11 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2
12 Dose-escalation Study of Oral CX-4945 Unknown status NCT00891280 Phase 1
13 A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Completed NCT01183598 Phase 1
14 A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease Completed NCT00412321 Phase 1
15 An Open-Label Trial of Tocilizumab in Schizophrenia Completed NCT01696929 Phase 1
16 Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Recruiting NCT02659930 Phase 1
17 Tocilizumab in Schizophrenia Not yet recruiting NCT02874573 Phase 1
18 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1
19 Epithelioid Hemangioma of Bone And Soft Tissue Completed NCT03169595
20 Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Completed NCT00695422
21 Castleman Disease Collaborative Network Biobank Recruiting NCT02871050
22 Unlock the Cell: Castleman's Disease Flow Cytometry Study Recruiting NCT02853968
23 International Registry for Patients With Castleman Disease Recruiting NCT02817997
24 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
25 Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Terminated NCT02080416 Early Phase 1
26 Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Withdrawn NCT02805868 Early Phase 1

Search NIH Clinical Center for Unicentric Castleman Disease

Genetic Tests for Unicentric Castleman Disease

Anatomical Context for Unicentric Castleman Disease

MalaCards organs/tissues related to Unicentric Castleman Disease:

39
Lymph Node, Prostate

Publications for Unicentric Castleman Disease

Articles related to Unicentric Castleman Disease:

(show all 18)
id Title Authors Year
1
Unicentric Castleman Disease: An Unusual Cause of An Isolated Neck Mass. ( 27660550 )
2016
2
Perivesical unicentric Castleman disease initially suspected to be metastatic prostate cancer. ( 27141204 )
2016
3
Complete resection of unicentric Castleman disease in the superior mediastinum: A case report. ( 27318017 )
2016
4
Case Report Unicentric Castleman disease located in the anterior mediastinum misdiagnosed as invasive thymoma: a case report. ( 26125875 )
2015
5
Intrapulmonary unicentric Castleman disease mimicking peripheral pulmonary malignancy. ( 26767055 )
2014
6
Unicentric Castleman disease: from screening mammography to PET/CT imaging. ( 25286148 )
2014
7
Endosonographic features of unicentric Castleman Disease. ( 26425506 )
2014
8
Iron-Refractory Microcytic Anemia as the Presenting Feature of Unicentric Castleman Disease in Children. ( 24367988 )
2013
9
Parapharengeal unicentric castleman disease with nephrotic syndrome. ( 23880810 )
2013
10
Unicentric Castleman disease relapsed after rituximab-CHOP chemotherapy or radiation therapy in an adolescent. ( 22258344 )
2012
11
Unicentric Castleman disease mimicking a pancreatic neoplasm. ( 22524754 )
2012
12
Treatment of unicentric Castleman disease with neoadjuvant rituximab. ( 21051400 )
2010
13
Cervical unicentric Castleman disease presenting as a neck mass: case report and review of the literature. ( 19444782 )
2009
14
A 5-year-old boy with unicentric Castleman disease affecting the mesentery: utility of serum IL-6 level and (18)F-FDG PET for diagnosis. ( 19730402 )
2009
15
Complete anemia reversal after surgical excision of mesenteric hyaline-vascular unicentric Castleman disease. ( 19865557 )
2009
16
Unicentric castleman disease is not clearly distinguished from multicentric type: a case report. ( 18765316 )
2008
17
Isolated microcytic anemia disclosing a unicentric Castleman disease: The interleukin-6/hepcidin pathway? ( 18549942 )
2008
18
Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. ( 17118850 )
2006

Variations for Unicentric Castleman Disease

Expression for Unicentric Castleman Disease

Search GEO for disease gene expression data for Unicentric Castleman Disease.

Pathways for Unicentric Castleman Disease

Pathways related to Unicentric Castleman Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
10.96 CRP SAA4

GO Terms for Unicentric Castleman Disease

Cellular components related to Unicentric Castleman Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 8.62 CRP SAA4

Biological processes related to Unicentric Castleman Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 acute-phase response GO:0006953 8.62 CRP SAA4

Sources for Unicentric Castleman Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....